BRPI0907776A2 - Composições e métodos para usar células estromais para aumentar o tratamento de danos ao sistema nervoso central - Google Patents

Composições e métodos para usar células estromais para aumentar o tratamento de danos ao sistema nervoso central

Info

Publication number
BRPI0907776A2
BRPI0907776A2 BRPI0907776-6A BRPI0907776A BRPI0907776A2 BR PI0907776 A2 BRPI0907776 A2 BR PI0907776A2 BR PI0907776 A BRPI0907776 A BR PI0907776A BR PI0907776 A2 BRPI0907776 A2 BR PI0907776A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
nervous system
central nervous
stromal cells
Prior art date
Application number
BRPI0907776-6A
Other languages
English (en)
Inventor
Michael Chopp
Original Assignee
Ford Henry Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ford Henry Health System filed Critical Ford Henry Health System
Publication of BRPI0907776A2 publication Critical patent/BRPI0907776A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0907776-6A 2008-02-28 2009-02-24 Composições e métodos para usar células estromais para aumentar o tratamento de danos ao sistema nervoso central BRPI0907776A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3236508P 2008-02-28 2008-02-28
PCT/US2009/034997 WO2009108632A1 (en) 2008-02-28 2009-02-24 Compositions and methods for using stromal cells to enhance treatment of central nervous system injuries

Publications (1)

Publication Number Publication Date
BRPI0907776A2 true BRPI0907776A2 (pt) 2015-07-14

Family

ID=41016448

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907776-6A BRPI0907776A2 (pt) 2008-02-28 2009-02-24 Composições e métodos para usar células estromais para aumentar o tratamento de danos ao sistema nervoso central

Country Status (10)

Country Link
US (1) US20110158969A1 (pt)
EP (1) EP2262512A1 (pt)
JP (1) JP2011513318A (pt)
KR (1) KR20110010694A (pt)
CN (1) CN102014935B (pt)
AU (1) AU2009219432A1 (pt)
BR (1) BRPI0907776A2 (pt)
CA (1) CA2753833A1 (pt)
MX (1) MX2010009540A (pt)
WO (1) WO2009108632A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962039B2 (en) * 2009-09-04 2015-02-24 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
PT2775928T (pt) 2011-11-08 2019-05-30 Auxocell Laboratories Inc Sistemas e métodos para processar células
US20170065638A1 (en) * 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
USD748462S1 (en) 2014-08-11 2016-02-02 Auxocell Laboratories, Inc. Centrifuge clip
US9993748B2 (en) 2014-08-11 2018-06-12 Auxocell Laboratories, Inc. Centrifuge clip and method
TWI559928B (en) * 2014-08-20 2016-12-01 Academia Sinica Methods for enhancing permeability to blood-brain barrier and uses thereof
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
GB2568928B (en) * 2017-12-01 2023-03-08 Young Cell Biomedical Tech Inc Neuroprotective composition, preparation process thereof and medical uses thereof
US20200397840A1 (en) * 2017-12-26 2020-12-24 Kao Corporation Cognitive Function Improvement Agent
US20210379151A1 (en) * 2018-10-03 2021-12-09 Ming-Che Shih Use of vegf at multiple doses to enhance permeability of blood brain barrier
KR20220070809A (ko) 2020-11-23 2022-05-31 아주대학교산학협력단 Ccl5 또는 ccl5 효능제를 유효성분으로 함유하는 중추신경계 손상 관련 질환 치료용 조성물
CN113940950A (zh) * 2021-10-27 2022-01-18 中国人民解放军军事科学院军事医学研究院 额骨间充质干细胞在治疗和/或预防动物创伤性脑损伤中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1183035E (pt) * 1999-05-14 2015-03-04 Ford Henry Health System Transplante de medula óssea para tratamento de acidente vascular cerebral
IL137672A0 (en) * 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
EP1658853A4 (en) * 2003-06-27 2009-07-08 Renomedix Inst Inc MEDIUM FOR INTERNAL ADMINISTRATION FOR DISEASES OF NERVES IN THE HEAD WITH MESENCYCLES AS AN ACTIVE SUBSTANCE

Also Published As

Publication number Publication date
JP2011513318A (ja) 2011-04-28
CN102014935A (zh) 2011-04-13
US20110158969A1 (en) 2011-06-30
AU2009219432A1 (en) 2009-09-03
MX2010009540A (es) 2011-02-21
CA2753833A1 (en) 2009-09-03
CN102014935B (zh) 2012-10-10
WO2009108632A1 (en) 2009-09-03
KR20110010694A (ko) 2011-02-07
WO2009108632A9 (en) 2009-11-12
EP2262512A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
BRPI0907776A2 (pt) Composições e métodos para usar células estromais para aumentar o tratamento de danos ao sistema nervoso central
BRPI0909817A2 (pt) uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos
BRPI1013829A2 (pt) composições e métodos para fermentação de biomassa
BRPI0918693A2 (pt) dispositivos para amostragem e métodos para concentração de microorganismos
BR112012000629A2 (pt) composições preservadas de células nk ativadas e métodos para usar as mesmas
ZA201008392B (en) Treatment of pluripotent cells
DK2574677T3 (da) Fremgangsmåder til celledyrkning
DK2675902T3 (da) Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
BRPI0921726A2 (pt) método e dispositivo para ativar células tronco
BRPI0920072A2 (pt) métodos para separação e caracterização de micro-organismos por agentes identificadores
BRPI0917993A2 (pt) composições de célula-tronco mesenquimal purificada e métodos de purificação de composições de célula-tronco mesenquimal purificda.
BRPI0910449A2 (pt) Processo para purificação de álcool de fermentação
BRPI1011226A2 (pt) métodos para tratar condições relacionadas ao cabelo
BRPI1008253A2 (pt) Metoso para tratar biomassa
BR112012001080A2 (pt) Combinações de substâncias ativas sinérgicas contendo feniltriazóis
BRPI0722183A2 (pt) Composições farmacêuticas para tratar depressão e ansiedade
BR112013015107A2 (pt) métodos e dispositivos para usar álcool isoperílico
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
BRPI0918713A2 (pt) composições e métodos para o rápido crescimento e detecção de microorganismos
BR112012003584A2 (pt) método e disposito para utilização de biomassa
BR112013013432A2 (pt) absorvente aprimorado e processo para remoção de inibidores de fermentação
BRPI0822264A2 (pt) Dapsona para tratar rosácea
DK2337573T3 (da) Valle til anvendelse i behandling af lymfocytopeni
ECSP12011970A (es) NUEVOS DERIVADOS DE (HETEROCICLO-PIPERIDINA CONDENSADA)-(PIPERAZINIL)-1-ALCANONA O DE (HETEROCICLO-PIRROLIDINA CONDENSADA)-(PIPERAZINIL)-1-ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
DK2310018T3 (da) Anvendelse af nifurtimox til behandling af giardiasis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.